Emerson Chen

GI oncologist and health services researcher at Oregon Health & Science University

[Axel Grothey @agrothey]

Pembro in “TMB high” (10+) cancers - paper published in Lancet Oncol. No difference in OS between TMB high and TMB low. Neverthelessless FDA approved. SMH. @OncoAlert

[Bernie Marini @Berninini]

Friendly reminder that surrogate endpoints like PFS only reduce study time by an average of 11 months - @IamEmchee, et al. 🙂 We shouldn’t proclaim new therapies as “new standard of care”, without showing OS or QOL benefit for patients. #ASCO2020 #asco20 https://t.co/rERjHZpb6Q

[Emerson Chen @IamEmchee]

Critical Care and the COVID-19 Outbreak in Italy: Early Experience and Forecast https://t.co/ONyLqS46op

[Ryan Huey, MD, MS @ryanhuey]

Dr. Christopher Booth reminds us about endpoints that matter to patients. #GI20

[Emerson Chen @IamEmchee]

Canada's Transparency With Clinical Trial Puts Pressure On U.S. FDA To Reveal More : Shots - Health News : NPR https://t.co/73w3s8jKSR

[Emerson Chen @IamEmchee]

@MWFriedberg It’s been looked at in oncology drug trials. https://t.co/jCh7W20gAZ

[Emerson Chen @IamEmchee]

Couldn’t agree more, would like to tell my patients how a new therapy will directly help them. “Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs” https://t.co/jMUDFvU5qw

[Emerson Chen @IamEmchee]

@docamitgs @NDP1001 @nicole_rich8 Beautiul study, May report too, curious about if DAA reduces mortality but has similar recurrent HCC, then would receipt of DAA influence survival outcome of adjuvant/consolidation systemic treatment (if ongoing trials are +)? What’s the HR in usual survival curve/Cox regression?

[Emerson Chen @IamEmchee]

Wow amazing online course that changed how I think about oncology drugs, and completed just in time before my first day as faculty tomorrow @edxonline #mooc https://t.co/TSpac3YAkr

[Elizabeth Warren @SenWarren]

I look forward to a response and hope Dr. @ScottGottliebMD will rectify his mistake & resign from his position at @Pfizer. It would send a strong message about the importance of integrity of current & former federal officials.

[Emerson Chen @IamEmchee]

@docamitgs @AASLDtweets @renumathyd @nicole_rich8 @MichiganLiver @GABOUALFA @NDP1001 @kwburak @NancyReau @dhjutsw1 Current U.S. cancer drug approval process allows multiple phase 3 trials to be run. 1) See FDA letter: https://t.co/G1cHh2pOZF. 2) See how fast drug trials can get required data in today’s age https://t.co/nlaYDoNSUI.

[Emerson Chen @IamEmchee]

Health policy conundrum, 1) gets cancer drug approved faster but more uncertainty 2) might not get drug approved but more certainty of clinical benefit https://t.co/nlaYDoNSUI

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

@GIcancerDoc @pashtoonkasi @aakonc @UqbaKhan @kmody29 @DrR_DUNNE @gabe_a_brooks @agrothey @utswcancer @ASCOPost great point.. raises the question, should one design a trial aimed at the 1) end point you can achieve or 2) the end point which is more meaningful?

[Emerson Chen @IamEmchee]

I find the sicker treatment-refractory patient tend to be on left and the healthier adjuvant/first-line metastatic patient on the right.

[Michael Fisch MD MPH @fischmd]

@barttels2 @cordekroon @oncology_bg @ASCO @ecancer @QueensCRI @scottrberry @cpgYALE @yzafar @MartinStockler @Prof_IanD @NicoleKuderer @JackWestMD The bargain of accelerated approvals and the spectrum of patient viewpoints on this issue was described brilliantly by @VPrasadMDMPH at #ASCO19

[Yousuf Zafar, MD MHS @yzafar]

Len Saltz @sloan_kettering listing no-value interventions in #colorectalcancer Anything to add or subtract? #ASCO19 #crcsm

[Tatiana Prowell, MD @tmprowell]

On interpreting #clinicaltrials: When you hear “A HR of __ & a __month diff in PFS,” consider what the control arm is. The interpretation of those #s differs if comparator is placebo/BSC or active control, & if active control, if new drug is an add on or replacement tx. #ASCO19

[Sam Sater, MD @HSaterMD]

ANNOUNCE failed to meet OS primary endpoint and Olaratumab will be withdrawn after previous initial FDA @US_FDA approval. #ASCO19 #ASCO2019 #sarcoma #pdgfra

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

In light of today’s #ASCO19 plenary, please read our latest @JAMAInternalMed paper on accelerated approval to understand this pathway’s trade offs. We even managed to sneak in a sentence about #olaratumab at the very last moment. https://t.co/VLUPRmK8b8 #ASCOplenary #sarcoma

[Michael Fisch MD MPH @fischmd]

“Clinical trials are there to serve patients, not the other way around.”
—@oncology_bg #ASCO19

#bcsm #lcsm #crcsm #mmsm

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

And here’s the story covered by @rrichardh in the NPR : https://t.co/rUnlBKaPeF

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

The biggest honor, however, is to have 2 editorials accompany our paper. I always lamented @RichardLehman1 ‘s retiring from BMJ blogs without getting chance to read his comment on my work. But now he has written an editorial instead with @cpgYALE . https://t.co/sQePfbrPDh 🙏